---
document_datetime: 2025-12-29 08:05:41
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/levetiracetam-accord.html
document_name: levetiracetam-accord.html
version: success
processing_time: 0.1279034
conversion_datetime: 2025-12-30 00:34:03.444278
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Levetiracetam Accord

[RSS](/en/individual-human-medicine.xml/66439)

##### Authorised

This medicine is authorised for use in the European Union

levetiracetam Medicine Human Authorised

On Monday, 12 January 2026, between 07:00 and 10:00 CET (Amsterdam time), this website will be unavailable due to scheduled maintenance.

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [More information on Levetiracetam Accord](#more-information-on-levetiracetam-accord-1319)
- [Topics](#topics)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

This is a summary of the European public assessment report (EPAR) for Levetiracetam Accord. It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Levetiracetam Accord.

Expand section

Collapse section

## What is Levetiracetam Accord and what is it used for?

Levetiracetam Accord is an epilepsy medicine. It can be used on its own in patients from 16 years of age with newly diagnosed epilepsy, to treat partial-onset seizures (fits) with or without secondary generalisation. This is a type of epilepsy where too much electrical activity in one side of the brain causes symptoms such as sudden, jerky movements of one part of the body, distorted hearing, sense of smell or vision, numbness, or a sudden sense of fear. Secondary generalisation occurs when the overactivity later reaches the whole brain.

Levetiracetam Accord can also be used as an add-on to other epilepsy medicines to treat:

- partial-onset seizures with or without generalisation in patients from 1 month of age;
- myoclonic seizures (short, shock-like jerks of a muscle or group of muscles) in patients from 12 years of age with juvenile myoclonic epilepsy;
- primary generalised tonic-clonic seizures (major fits, including loss of consciousness) in patients from 12 years of age with idiopathic generalised epilepsy (the type of epilepsy that is thought to be inherited).

Levetiracetam Accord contains the active substance levetiracetam and is a 'generic medicine'. This means that Levetiracetam Accord contains the same active substance and works in the same way as a 'reference medicine' already authorised in the EU called Keppra.

## How is Levetiracetam Accord used?

Levetiracetam Accord is available as tablets to be swallowed with liquid. It can only be obtained with a prescription.

The usual starting dose in patients over 12 years weighing more than 50 kg is 500 mg twice a day. The daily dose can be increased up to 1,500 mg twice a day. For patients aged between one month and 17 years weighing less than 50 kg, the dose depends on body weight.

For more information about using Levetiracetam Accord, see the package leaflet or contact your doctor or pharmacist.

## How does Levetiracetam Accord work?

The active substance in Levetiracetam Accord, levetiracetam, is an epilepsy medicine. Epilepsy is caused by excessive electrical activity in the brain. The exact way in which levetiracetam works is unclear but it attaches to a protein called synaptic vesicle protein 2A, which is involved in the release of chemical messengers from nerve cells. This helps Levetiracetam Accord to stabilise electrical activity in the brain and prevent seizures.

## How has Levetiracetam Accord been studied?

The company provided data from the published literature on levetiracetam. Studies on the benefits and risks of the active substance in the authorised uses have already been carried out with the reference medicine, Keppra, and do not need to be repeated for Levetiracetam Accord

As for every medicine, the company provided data on the quality of Levetiracetam Accord. The company also carried out studies that showed that it is 'bioequivalent' to the reference medicine. Two medicines are bioequivalent when they produce the same levels of the active substance in the body and are therefore expected to have the same effect.

## What are the benefits and risks of Levetiracetam Accord?

Because Levetiracetam Accord is a generic medicine and is bioequivalent to the reference medicine, its benefits and risks are taken as being the same as the reference medicine's.

## Why is Levetiracetam Accord authorised in the EU?

The European Medicines Agency concluded that, in accordance with EU requirements, Levetiracetam Accord has been shown to have comparable quality and to be bioequivalent to Keppra. Therefore, the Agency's view was that, as for Keppra, the benefits of Levetiracetam Accord outweigh the identified risks and it can be authorised for use in the EU.

## What measures are being taken to ensure the safe and effective use of Levetiracetam Accord?

Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Levetiracetam Accord have been included in the summary of product characteristics and the package leaflet.

As for all medicines, data on the use of Levetiracetam Accord are continuously monitored. Suspected side effects reported with Levetiracetam Accord are carefully evaluated and any necessary action taken to protect patients.

## Other information about Levetiracetam Accord

Levetiracetam Accord received a marketing authorisation valid throughout the EU on 3 October 2011.

Levetiracetam Accord : EPAR - Summary for the public

Reference Number: EMA/683201/2011

English (EN) (147.47 KB - PDF)

**First published:** 14/10/2011

**Last updated:** 10/09/2021

[View](/en/documents/overview/levetiracetam-accord-epar-summary-public_en.pdf)

[Other languages (22)](#file-language-dropdown-747)

български (BG) (174.64 KB - PDF)

**First published:**

14/10/2011

**Last updated:**

10/09/2021

[View](/bg/documents/overview/levetiracetam-accord-epar-summary-public_bg.pdf)

español (ES) (141.04 KB - PDF)

**First published:**

14/10/2011

**Last updated:**

10/09/2021

[View](/es/documents/overview/levetiracetam-accord-epar-summary-public_es.pdf)

čeština (CS) (171.01 KB - PDF)

**First published:**

14/10/2011

**Last updated:**

10/09/2021

[View](/cs/documents/overview/levetiracetam-accord-epar-summary-public_cs.pdf)

dansk (DA) (140.12 KB - PDF)

**First published:**

14/10/2011

**Last updated:**

10/09/2021

[View](/da/documents/overview/levetiracetam-accord-epar-summary-public_da.pdf)

Deutsch (DE) (152.03 KB - PDF)

**First published:**

14/10/2011

**Last updated:**

10/09/2021

[View](/de/documents/overview/levetiracetam-accord-epar-summary-public_de.pdf)

eesti keel (ET) (136.44 KB - PDF)

**First published:**

14/10/2011

**Last updated:**

10/09/2021

[View](/et/documents/overview/levetiracetam-accord-epar-summary-public_et.pdf)

ελληνικά (EL) (175.03 KB - PDF)

**First published:**

14/10/2011

**Last updated:**

10/09/2021

[View](/el/documents/overview/levetiracetam-accord-epar-summary-public_el.pdf)

français (FR) (149.5 KB - PDF)

**First published:**

14/10/2011

**Last updated:**

10/09/2021

[View](/fr/documents/overview/levetiracetam-accord-epar-summary-public_fr.pdf)

hrvatski (HR) (168.82 KB - PDF)

**First published:**

14/10/2011

**Last updated:**

10/09/2021

[View](/hr/documents/overview/levetiracetam-accord-epar-summary-public_hr.pdf)

italiano (IT) (147.55 KB - PDF)

**First published:**

14/10/2011

**Last updated:**

10/09/2021

[View](/it/documents/overview/levetiracetam-accord-epar-summary-public_it.pdf)

latviešu valoda (LV) (186.41 KB - PDF)

**First published:**

14/10/2011

**Last updated:**

10/09/2021

[View](/lv/documents/overview/levetiracetam-accord-epar-summary-public_lv.pdf)

lietuvių kalba (LT) (168.36 KB - PDF)

**First published:**

14/10/2011

**Last updated:**

10/09/2021

[View](/lt/documents/overview/levetiracetam-accord-epar-summary-public_lt.pdf)

magyar (HU) (162.29 KB - PDF)

**First published:**

14/10/2011

**Last updated:**

10/09/2021

[View](/hu/documents/overview/levetiracetam-accord-epar-summary-public_hu.pdf)

Malti (MT) (171.97 KB - PDF)

**First published:**

14/10/2011

**Last updated:**

10/09/2021

[View](/mt/documents/overview/levetiracetam-accord-epar-summary-public_mt.pdf)

Nederlands (NL) (149.82 KB - PDF)

**First published:**

14/10/2011

**Last updated:**

10/09/2021

[View](/nl/documents/overview/levetiracetam-accord-epar-summary-public_nl.pdf)

polski (PL) (172.55 KB - PDF)

**First published:**

14/10/2011

**Last updated:**

10/09/2021

[View](/pl/documents/overview/levetiracetam-accord-epar-summary-public_pl.pdf)

português (PT) (140.61 KB - PDF)

**First published:**

14/10/2011

**Last updated:**

10/09/2021

[View](/pt/documents/overview/levetiracetam-accord-epar-summary-public_pt.pdf)

română (RO) (160.05 KB - PDF)

**First published:**

14/10/2011

**Last updated:**

10/09/2021

[View](/ro/documents/overview/levetiracetam-accord-epar-summary-public_ro.pdf)

slovenčina (SK) (170.48 KB - PDF)

**First published:**

14/10/2011

**Last updated:**

10/09/2021

[View](/sk/documents/overview/levetiracetam-accord-epar-summary-public_sk.pdf)

slovenščina (SL) (159.15 KB - PDF)

**First published:**

14/10/2011

**Last updated:**

10/09/2021

[View](/sl/documents/overview/levetiracetam-accord-epar-summary-public_sl.pdf)

Suomi (FI) (145.98 KB - PDF)

**First published:**

14/10/2011

**Last updated:**

10/09/2021

[View](/fi/documents/overview/levetiracetam-accord-epar-summary-public_fi.pdf)

svenska (SV) (138.28 KB - PDF)

**First published:**

14/10/2011

**Last updated:**

10/09/2021

[View](/sv/documents/overview/levetiracetam-accord-epar-summary-public_sv.pdf)

Levetiracetam Accord : EPAR - Risk management plan

English (EN) (281.48 KB - PDF)

**First published:** 11/07/2025

[View](/en/documents/rmp/levetiracetam-accord-epar-risk-management-plan_en.pdf)

## Product information

Levetiracetam Accord : EPAR - Product Information

English (EN) (451.39 KB - PDF)

**First published:** 14/10/2011

**Last updated:** 09/12/2025

[View](/en/documents/product-information/levetiracetam-accord-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-460)

български (BG) (592.61 KB - PDF)

**First published:**

14/10/2011

**Last updated:**

09/12/2025

[View](/bg/documents/product-information/levetiracetam-accord-epar-product-information_bg.pdf)

español (ES) (503.5 KB - PDF)

**First published:**

14/10/2011

**Last updated:**

09/12/2025

[View](/es/documents/product-information/levetiracetam-accord-epar-product-information_es.pdf)

čeština (CS) (563.43 KB - PDF)

**First published:**

14/10/2011

**Last updated:**

09/12/2025

[View](/cs/documents/product-information/levetiracetam-accord-epar-product-information_cs.pdf)

dansk (DA) (484.23 KB - PDF)

**First published:**

14/10/2011

**Last updated:**

09/12/2025

[View](/da/documents/product-information/levetiracetam-accord-epar-product-information_da.pdf)

Deutsch (DE) (472.68 KB - PDF)

**First published:**

14/10/2011

**Last updated:**

09/12/2025

[View](/de/documents/product-information/levetiracetam-accord-epar-product-information_de.pdf)

eesti keel (ET) (480.77 KB - PDF)

**First published:**

14/10/2011

**Last updated:**

09/12/2025

[View](/et/documents/product-information/levetiracetam-accord-epar-product-information_et.pdf)

ελληνικά (EL) (575.21 KB - PDF)

**First published:**

14/10/2011

**Last updated:**

09/12/2025

[View](/el/documents/product-information/levetiracetam-accord-epar-product-information_el.pdf)

français (FR) (506.69 KB - PDF)

**First published:**

14/10/2011

**Last updated:**

09/12/2025

[View](/fr/documents/product-information/levetiracetam-accord-epar-product-information_fr.pdf)

hrvatski (HR) (580.99 KB - PDF)

**First published:**

14/10/2011

**Last updated:**

09/12/2025

[View](/hr/documents/product-information/levetiracetam-accord-epar-product-information_hr.pdf)

íslenska (IS) (509.81 KB - PDF)

**First published:**

14/10/2011

**Last updated:**

09/12/2025

[View](/is/documents/product-information/levetiracetam-accord-epar-product-information_is.pdf)

italiano (IT) (553 KB - PDF)

**First published:**

14/10/2011

**Last updated:**

09/12/2025

[View](/it/documents/product-information/levetiracetam-accord-epar-product-information_it.pdf)

latviešu valoda (LV) (543.23 KB - PDF)

**First published:**

14/10/2011

**Last updated:**

09/12/2025

[View](/lv/documents/product-information/levetiracetam-accord-epar-product-information_lv.pdf)

lietuvių kalba (LT) (593.65 KB - PDF)

**First published:**

14/10/2011

**Last updated:**

09/12/2025

[View](/lt/documents/product-information/levetiracetam-accord-epar-product-information_lt.pdf)

magyar (HU) (565.06 KB - PDF)

**First published:**

14/10/2011

**Last updated:**

09/12/2025

[View](/hu/documents/product-information/levetiracetam-accord-epar-product-information_hu.pdf)

Malti (MT) (612.39 KB - PDF)

**First published:**

14/10/2011

**Last updated:**

09/12/2025

[View](/mt/documents/product-information/levetiracetam-accord-epar-product-information_mt.pdf)

Nederlands (NL) (327.14 KB - PDF)

**First published:**

14/10/2011

**Last updated:**

09/12/2025

[View](/nl/documents/product-information/levetiracetam-accord-epar-product-information_nl.pdf)

norsk (NO) (567.94 KB - PDF)

**First published:**

14/10/2011

**Last updated:**

09/12/2025

[View](/no/documents/product-information/levetiracetam-accord-epar-product-information_no.pdf)

polski (PL) (574.36 KB - PDF)

**First published:**

14/10/2011

**Last updated:**

09/12/2025

[View](/pl/documents/product-information/levetiracetam-accord-epar-product-information_pl.pdf)

português (PT) (538.24 KB - PDF)

**First published:**

14/10/2011

**Last updated:**

09/12/2025

[View](/pt/documents/product-information/levetiracetam-accord-epar-product-information_pt.pdf)

română (RO) (546.86 KB - PDF)

**First published:**

14/10/2011

**Last updated:**

09/12/2025

[View](/ro/documents/product-information/levetiracetam-accord-epar-product-information_ro.pdf)

slovenčina (SK) (526.35 KB - PDF)

**First published:**

14/10/2011

**Last updated:**

09/12/2025

[View](/sk/documents/product-information/levetiracetam-accord-epar-product-information_sk.pdf)

slovenščina (SL) (505.77 KB - PDF)

**First published:**

14/10/2011

**Last updated:**

09/12/2025

[View](/sl/documents/product-information/levetiracetam-accord-epar-product-information_sl.pdf)

Suomi (FI) (517.14 KB - PDF)

**First published:**

14/10/2011

**Last updated:**

09/12/2025

[View](/fi/documents/product-information/levetiracetam-accord-epar-product-information_fi.pdf)

svenska (SV) (484.94 KB - PDF)

**First published:**

14/10/2011

**Last updated:**

09/12/2025

[View](/sv/documents/product-information/levetiracetam-accord-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** VR/0000265690 30/04/2025

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Levetiracetam Accord : EPAR - All Authorised presentations

English (EN) (12.79 KB - PDF)

**First published:** 14/10/2011

**Last updated:** 18/09/2012

[View](/en/documents/all-authorised-presentations/levetiracetam-accord-epar-all-authorised-presentations_en.pdf)

[Other languages (23)](#file-language-dropdown-281)

български (BG) (34.69 KB - PDF)

**First published:**

14/10/2011

**Last updated:**

18/09/2012

[View](/bg/documents/all-authorised-presentations/levetiracetam-accord-epar-all-authorised-presentations_bg.pdf)

español (ES) (11.77 KB - PDF)

**First published:**

14/10/2011

**Last updated:**

18/09/2012

[View](/es/documents/all-authorised-presentations/levetiracetam-accord-epar-all-authorised-presentations_es.pdf)

čeština (CS) (18.7 KB - PDF)

**First published:**

14/10/2011

**Last updated:**

18/09/2012

[View](/cs/documents/all-authorised-presentations/levetiracetam-accord-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (13.87 KB - PDF)

**First published:**

14/10/2011

**Last updated:**

18/09/2012

[View](/da/documents/all-authorised-presentations/levetiracetam-accord-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (13.42 KB - PDF)

**First published:**

14/10/2011

**Last updated:**

18/09/2012

[View](/de/documents/all-authorised-presentations/levetiracetam-accord-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (13.92 KB - PDF)

**First published:**

14/10/2011

**Last updated:**

18/09/2012

[View](/et/documents/all-authorised-presentations/levetiracetam-accord-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (34.58 KB - PDF)

**First published:**

14/10/2011

**Last updated:**

18/09/2012

[View](/el/documents/all-authorised-presentations/levetiracetam-accord-epar-all-authorised-presentations_el.pdf)

français (FR) (14.22 KB - PDF)

**First published:**

14/10/2011

**Last updated:**

18/09/2012

[View](/fr/documents/all-authorised-presentations/levetiracetam-accord-epar-all-authorised-presentations_fr.pdf)

íslenska (IS) (13.63 KB - PDF)

**First published:**

14/10/2011

**Last updated:**

18/09/2012

[View](/is/documents/all-authorised-presentations/levetiracetam-accord-epar-all-authorised-presentations_is.pdf)

italiano (IT) (13.45 KB - PDF)

**First published:**

14/10/2011

**Last updated:**

18/09/2012

[View](/it/documents/all-authorised-presentations/levetiracetam-accord-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (26.26 KB - PDF)

**First published:**

14/10/2011

**Last updated:**

18/09/2012

[View](/lv/documents/all-authorised-presentations/levetiracetam-accord-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (26.75 KB - PDF)

**First published:**

14/10/2011

**Last updated:**

18/09/2012

[View](/lt/documents/all-authorised-presentations/levetiracetam-accord-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (24.66 KB - PDF)

**First published:**

14/10/2011

**Last updated:**

18/09/2012

[View](/hu/documents/all-authorised-presentations/levetiracetam-accord-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (24.64 KB - PDF)

**First published:**

14/10/2011

**Last updated:**

18/09/2012

[View](/mt/documents/all-authorised-presentations/levetiracetam-accord-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (13.13 KB - PDF)

**First published:**

14/10/2011

**Last updated:**

18/09/2012

[View](/nl/documents/all-authorised-presentations/levetiracetam-accord-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (13.89 KB - PDF)

**First published:**

14/10/2011

**Last updated:**

18/09/2012

[View](/no/documents/all-authorised-presentations/levetiracetam-accord-epar-all-authorised-presentations_no.pdf)

polski (PL) (18.6 KB - PDF)

**First published:**

14/10/2011

**Last updated:**

18/09/2012

[View](/pl/documents/all-authorised-presentations/levetiracetam-accord-epar-all-authorised-presentations_pl.pdf)

português (PT) (14.61 KB - PDF)

**First published:**

14/10/2011

**Last updated:**

18/09/2012

[View](/pt/documents/all-authorised-presentations/levetiracetam-accord-epar-all-authorised-presentations_pt.pdf)

română (RO) (24.55 KB - PDF)

**First published:**

14/10/2011

**Last updated:**

18/09/2012

[View](/ro/documents/all-authorised-presentations/levetiracetam-accord-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (19.76 KB - PDF)

**First published:**

14/10/2011

**Last updated:**

18/09/2012

[View](/sk/documents/all-authorised-presentations/levetiracetam-accord-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (14.05 KB - PDF)

**First published:**

14/10/2011

**Last updated:**

18/09/2012

[View](/sl/documents/all-authorised-presentations/levetiracetam-accord-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (16.12 KB - PDF)

**First published:**

14/10/2011

**Last updated:**

18/09/2012

[View](/fi/documents/all-authorised-presentations/levetiracetam-accord-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (12.94 KB - PDF)

**First published:**

14/10/2011

**Last updated:**

18/09/2012

[View](/sv/documents/all-authorised-presentations/levetiracetam-accord-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine Levetiracetam Accord Active substance levetiracetam International non-proprietary name (INN) or common name levetiracetam Therapeutic area (MeSH) Epilepsy Anatomical therapeutic chemical (ATC) code N03AX14

### Pharmacotherapeutic group

Antiepileptics

### Therapeutic indication

Levetiracetam is indicated as monotherapy in the treatment of partial-onset seizures with or without secondary generalisation in patients from 16 years of age with newly diagnosed epilepsy.

Levetiracetam is indicated as adjunctive therapy:

- in the treatment of partial-onset seizures with or without secondary generalisation in adults, children and infants from one month of age with epilepsy;
- in the treatment of myoclonic seizures in adults and adolescents from 12 years of age with juvenile myoclonic epilepsy;
- in the treatment of primary generalised tonic-clonic seizures in adults and adolescents from 12 years of age with idiopathic generalised epilepsy.

## Authorisation details

EMA product number EMEA/H/C/002290

Generic

This is a generic medicine, which is developed to be the same as a medicine that has already been authorised, called the reference medicine. A generic medicine contains the same active substance(s) as the reference medicine, and is used at the same dose(s) to treat the same disease(s). For more information, see [Generic and hybrid medicines](/node/69107) .

Marketing authorisation holder

Accord Healthcare S.L.U.

Edificio Este Planta 6a

Opinion adopted 21/07/2011 Marketing authorisation issued 03/10/2011 Revision 20

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Levetiracetam Accord : EPAR - Procedural steps taken and scientific information after authorisation

English (EN) (158.44 KB - PDF)

**First published:** 09/01/2025

**Last updated:** 09/12/2025

[View](/en/documents/procedural-steps-after/levetiracetam-accord-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf)

Levetiracetam Accord : EPAR - Procedural steps taken and scientific information after authorisation (archive)

English (EN) (212.71 KB - PDF)

**First published:** 18/09/2012

**Last updated:** 09/01/2025

[View](/en/documents/procedural-steps-after/levetiracetam-accord-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf)

## Initial marketing authorisation documents

Levetiracetam Accord : EPAR - Public assessment report

Adopted

Reference Number: EMA767403/2011

English (EN) (184.59 KB - PDF)

**First published:** 14/10/2011

**Last updated:** 14/10/2011

[View](/en/documents/assessment-report/levetiracetam-accord-epar-public-assessment-report_en.pdf)

CHMP summary of positive opinion for Levetiracetam Accord

Adopted

Reference Number: EMA/CHMP/551332/2011

English (EN) (68.14 KB - PDF)

**First published:** 22/07/2011

**Last updated:** 22/07/2011

[View](/en/documents/smop-initial/chmp-summary-positive-opinion-levetiracetam-accord_en.pdf)

#### More information on Levetiracetam Accord

Questions and answers on generic medicines

Reference Number: EMA/393905/2006 Rev. 2

English (EN) (66.45 KB - PDF)

**First published:** 09/07/2007

**Last updated:** 07/12/2012

[View](/en/documents/other/questions-and-answers-generic-medicines_en.pdf)

[Other languages (22)](#file-language-dropdown-573)

български (BG) (93.16 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/bg/documents/other/questions-and-answers-generic-medicines_bg.pdf)

español (ES) (68.3 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/es/documents/other/questions-and-answers-generic-medicines_es.pdf)

čeština (CS) (87.71 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/cs/documents/other/questions-and-answers-generic-medicines_cs.pdf)

dansk (DA) (66.79 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/da/documents/other/questions-and-answers-generic-medicines_da.pdf)

Deutsch (DE) (67.55 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/de/documents/other/questions-and-answers-generic-medicines_de.pdf)

eesti keel (ET) (65.21 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/et/documents/other/questions-and-answers-generic-medicines_et.pdf)

ελληνικά (EL) (91.29 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/el/documents/other/questions-and-answers-generic-medicines_el.pdf)

français (FR) (68.35 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/fr/documents/other/questions-and-answers-generic-medicines_fr.pdf)

hrvatski (HR) (87.8 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/hr/documents/other/questions-and-answers-generic-medicines_hr.pdf)

italiano (IT) (67.62 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/it/documents/other/questions-and-answers-generic-medicines_it.pdf)

latviešu valoda (LV) (111.81 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/lv/documents/other/questions-and-answers-generic-medicines_lv.pdf)

lietuvių kalba (LT) (86.76 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/lt/documents/other/questions-and-answers-generic-medicines_lt.pdf)

magyar (HU) (85.76 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/hu/documents/other/questions-and-answers-generic-medicines_hu.pdf)

Malti (MT) (89.35 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/mt/documents/other/questions-and-answers-generic-medicines_mt.pdf)

Nederlands (NL) (66.81 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/nl/documents/other/questions-and-answers-generic-medicines_nl.pdf)

polski (PL) (88.51 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/pl/documents/other/questions-and-answers-generic-medicines_pl.pdf)

português (PT) (68.32 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/pt/documents/other/questions-and-answers-generic-medicines_pt.pdf)

română (RO) (86.9 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/ro/documents/other/questions-and-answers-generic-medicines_ro.pdf)

slovenčina (SK) (87.73 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/sk/documents/other/questions-and-answers-generic-medicines_sk.pdf)

slovenščina (SL) (84.8 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/sl/documents/other/questions-and-answers-generic-medicines_sl.pdf)

Suomi (FI) (66.21 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/fi/documents/other/questions-and-answers-generic-medicines_fi.pdf)

svenska (SV) (67.11 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/sv/documents/other/questions-and-answers-generic-medicines_sv.pdf)

#### Topics

- [Generic and hybrid medicines](https://www.ema.europa.eu/en/search?f%5B0%5D=ema_search_topics%3A54)
- [Medicines](https://www.ema.europa.eu/en/search?f%5B0%5D=ema_search_topics%3A61)

**This page was last updated on** 09/12/2025

## Share this page

[Back to top](#main-content)